

S1 Table. Treatment regimens according to the risk group

Variable	Low-risk group (n=16)	High-risk group (n=65)	p-value
B-NHL	8 (50.0)	29 (44.6)	0.239
DA-EPOCH-R	5 (31.2)	11 (16.9)	
HyperCVAD	3 (18.8)	25 (38.5)	

Values are presented as number (%). B-NHL, cyclophosphamide and prednisone followed by cycles containing ifosfamide; high-dose methotrexate, vincristine, dexamethasone, and either doxorubicin or etoposide/cytarabine; or intrathecal triple therapy; DA-EPOCH-R, dose-adjusted infusional etoposide, doxorubicin, and vincristine with prednisone, cyclophosphamide, and rituximab; HyperCVAD, hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone with rituximab or without rituximab.